S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Options Trading Plan–Perfect For Beginners (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Options Trading Plan–Perfect For Beginners (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Options Trading Plan–Perfect For Beginners (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
Experts: "NVIDIA Bubble" Could Affect Entire Market (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Options Trading Plan–Perfect For Beginners (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
Small Caps That Have Priced In A Hard Landing For Big Upside
NASDAQ:QDEL

QuidelOrtho (QDEL) Stock Forecast, Price & News

$71.56
-0.07 (-0.10%)
(As of 09/25/2023 ET)
Compare
Today's Range
$70.83
$72.08
50-Day Range
$71.56
$88.63
52-Week Range
$66.88
$102.00
Volume
295,611 shs
Average Volume
460,696 shs
Market Capitalization
$4.78 billion
P/E Ratio
108.43
Dividend Yield
N/A
Price Target
$119.83

QuidelOrtho MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
67.5% Upside
$119.83 Price Target
Short Interest
Healthy
3.71% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
0.84mentions of QuidelOrtho in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
9.07%
From $4.96 to $5.41 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.97 out of 5 stars

Medical Sector

55th out of 962 stocks

Diagnostic Substances Industry

1st out of 13 stocks


QDEL stock logo

About QuidelOrtho (NASDAQ:QDEL) Stock

QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies and solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.

QDEL Price History

QDEL Stock News Headlines

QuidelOrtho Corporation
"This Could be the Biggest Stock Story of 2023"
A.I. is set to create $7 trillion in new wealth but most investors are buying the wrong stocks. Learn what Wall Street insiders are buying here.
Should You Add QuidelOrtho (QDEL) to Your Portfolio?
Where QuidelOrtho Stands With Analysts
"This Could be the Biggest Stock Story of 2023"
A.I. is set to create $7 trillion in new wealth but most investors are buying the wrong stocks. Learn what Wall Street insiders are buying here.
Craig-Hallum Keeps Their Buy Rating on QuidelOrtho (QDEL)
QuidelOrtho: A Tough Call To Make Right Now
QuidelOrtho Corp.
See More Headlines
Receive QDEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for QuidelOrtho and its competitors with MarketBeat's FREE daily newsletter.

QDEL Company Calendar

Last Earnings
8/08/2023
Today
9/25/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:QDEL
CUSIP
74838J10
Employees
7,000
Year Founded
1979

Price Target and Rating

Average Stock Price Forecast
$119.83
High Stock Price Forecast
$173.00
Low Stock Price Forecast
$85.00
Forecasted Upside/Downside
+67.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$548.70 million
Pretax Margin
2.15%

Debt

Sales & Book Value

Annual Sales
$3.27 billion
Cash Flow
$18.21 per share
Book Value
$74.71 per share

Miscellaneous

Free Float
65,322,000
Market Cap
$4.78 billion
Optionable
Optionable
Beta
0.27

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Douglas C. BryantMr. Douglas C. Bryant (Age 65)
    Pres, CEO & Director
    Comp: $4.82M
  • Mr. Joseph M. Busky CPA (Age 55)
    Chief Financial Officer
    Comp: $1.47M
  • Mr. Robert J. Bujarski J.D. (Age 54)
    Exec. VP & COO
    Comp: $2.62M
  • Ms. Michelle A. Hodges (Age 63)
    Sr. VP & Gen. Counsel
    Comp: $1.8M
  • Dr. Werner Kroll Ph.D. (Age 66)
    Sr. VP of R&D
    Comp: $1.25M
  • Ms. Louise M. Brandy
    Sr. VP & Chief Information Officer
  • Mr. Patrick E. Klein
    Chief Admin. Officer
  • Ruben Argueta
    Director of Investor Relations
  • Mr. William J. FerenczyMr. William J. Ferenczy (Age 67)
    Point of Care Bus. Unit Leader
  • Mr. Michael S. Iskra (Age 53)
    Exec. VP & Chief Commercial Officer













QDEL Stock - Frequently Asked Questions

Should I buy or sell QuidelOrtho stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for QuidelOrtho in the last year. There are currently 2 hold ratings, 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" QDEL shares.
View QDEL analyst ratings
or view top-rated stocks.

What is QuidelOrtho's stock price forecast for 2023?

5 equities research analysts have issued 12-month target prices for QuidelOrtho's stock. Their QDEL share price forecasts range from $85.00 to $173.00. On average, they anticipate the company's stock price to reach $119.83 in the next twelve months. This suggests a possible upside of 67.5% from the stock's current price.
View analysts price targets for QDEL
or view top-rated stocks among Wall Street analysts.

How have QDEL shares performed in 2023?

QuidelOrtho's stock was trading at $85.67 at the beginning of the year. Since then, QDEL shares have decreased by 16.5% and is now trading at $71.56.
View the best growth stocks for 2023 here
.

When is QuidelOrtho's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our QDEL earnings forecast
.

How were QuidelOrtho's earnings last quarter?

QuidelOrtho Co. (NASDAQ:QDEL) released its earnings results on Tuesday, August, 8th. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.23 by $0.03. The company had revenue of $665.10 million for the quarter, compared to analyst estimates of $615.11 million. QuidelOrtho had a net margin of 1.43% and a trailing twelve-month return on equity of 7.65%. The business's revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter last year, the business earned $2.11 earnings per share.

What guidance has QuidelOrtho issued on next quarter's earnings?

QuidelOrtho updated its FY 2023 earnings guidance on Wednesday, August, 9th. The company provided earnings per share (EPS) guidance of $4.85-$5.30 for the period, compared to the consensus estimate of $5.34. The company issued revenue guidance of $2.88 billion-$3.08 billion, compared to the consensus revenue estimate of $3.00 billion.

What is Doug Bryant's approval rating as QuidelOrtho's CEO?

47 employees have rated QuidelOrtho Chief Executive Officer Doug Bryant on Glassdoor.com. Doug Bryant has an approval rating of 76% among the company's employees.

What other stocks do shareholders of QuidelOrtho own?

Based on aggregate information from My MarketBeat watchlists, some companies that other QuidelOrtho investors own include NVIDIA (NVDA), DocuSign (DOCU), Tesla (TSLA), PayPal (PYPL), Shopify (SHOP), Block (SQ), Teladoc Health (TDOC), Netflix (NFLX), Advanced Micro Devices (AMD) and Zoom Video Communications (ZM).

What is QuidelOrtho's stock symbol?

QuidelOrtho trades on the NASDAQ under the ticker symbol "QDEL."

Who are QuidelOrtho's major shareholders?

QuidelOrtho's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.50%), ArrowMark Colorado Holdings LLC (4.83%), Senvest Management LLC (4.65%), State Street Corp (2.33%), JPMorgan Chase & Co. (1.79%) and Geode Capital Management LLC (1.27%). Insiders that own company stock include Charles P Slacik, Douglas C Bryant, Mary Lake Ph D Polan, Werner Kroll, William J Ferenczy and William J Ferenczy.
View institutional ownership trends
.

How do I buy shares of QuidelOrtho?

Shares of QDEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is QuidelOrtho's stock price today?

One share of QDEL stock can currently be purchased for approximately $71.56.

How much money does QuidelOrtho make?

QuidelOrtho (NASDAQ:QDEL) has a market capitalization of $4.78 billion and generates $3.27 billion in revenue each year. The company earns $548.70 million in net income (profit) each year or $0.66 on an earnings per share basis.

How many employees does QuidelOrtho have?

The company employs 7,000 workers across the globe.

How can I contact QuidelOrtho?

QuidelOrtho's mailing address is 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA, 92121. The official website for the company is www.quidel.com. The company can be reached via phone at (800) 874-1517, via email at rargueta@quidel.com, or via fax at 858-453-4338.

This page (NASDAQ:QDEL) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -